CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 156 enrolled
Drug / intervention
Seroquel +1 moredrug
Likely dose
Seroquel 400 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00674765
NCT00674765Phase 2Completed
CompareCT.gov

A Phase II Double-blind, Placebo-controlled Trial of Quetiapine for Frequent, Heavy Drinkers (Seroquel2)

University of Pennsylvania·interventional·Posted May 8, 2008·Updated Sep 17, 2014

In Brief

A Phase 2 clinical trial evaluating Seroquel and Placebo for Alcoholism. Completed, enrolled 156 participants across 1 site.

Detailed Summary

The purpose of this study is to examine the effects of quetiapine in reducing percent heavy drinking days and increasing percent abstinent days in alcohol dependent patients who are frequent heavy drinkers.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlcoholism
CountriesUnited States
CollaboratorsNational Institute on Alcohol Abuse and Alcoholism (NIAAA)

Timeline

Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMay 8, 2008
Enrollment StartJan 1, 2008
Primary CompletionJan 1, 2013
Study CompletionJan 1, 2014
TodayJul 2, 2026
Enrollment to primary: 5 yearsPosted 18.2 years ago

Interventions

Seroqueldrug

400 mg/day

Placebodrug

400 mg/day